Introduction {#s1}
============

The randomised controlled trial (RCT) provides the most reliable evidence for evaluating the effects of health care interventions [@pmed.1000368-Barton1],[@pmed.1000368-Sackett1], but the successful conduct of clinical RCTs is often hindered by recruitment difficulties [@pmed.1000368-Lovato1]. Inadequate recruitment reduces the power of studies to detect significant intervention effects [@pmed.1000368-Swanson1], causes delays (which may affect the generalizability of the study if standard care changes over time), increases costs, and can lead to failure to complete trials [@pmed.1000368-Walson1],[@pmed.1000368-Easterbrook1]. With increasing reliance on clinical RCT findings for clinical and regulatory decision making, the success of future RCTs depends on employing effective and efficient methods for recruiting study participants [@pmed.1000368-Baines1].

Historically recruitment of participants for RCTs has been by "trial and error" [@pmed.1000368-Zifferblatt1], by using a number of different strategies and modifying strategies according to the observed effects on recruitment. More recently, novel strategies have been developed to facilitate adequate and timely recruitment [@pmed.1000368-Lovato1],[@pmed.1000368-Swanson1]. Although there have been two previous systematic reviews on strategies to enhance recruitment to research [@pmed.1000368-Mapstone1],[@pmed.1000368-Watson1], they identified specific individual interventions. However, these interventions could not be combined to offer useful general advice for recruitment for clinical RCTs.

The aim of this study was to identify effective recruitment strategies for clinical RCTs by systematically reviewing randomised studies that compare consent rates, or other methods of measuring consent for two or more recruitment methods used, to approach potential RCT participants for trial participation (these studies are termed recruitment trials).

Methods {#s2}
=======

A protocol for this systematic review had not been registered before the review commenced, although the abstracts of previous versions of this systematic review were published in 2002 (International Clinical Trials Symposium: improving health care in the new millennium) [@pmed.1000368-Caldwell1] and 2007 (3rd International Clinical Trials Symposium) [@pmed.1000368-Caldwell2] ([Text S1](#pmed.1000368.s001){ref-type="supplementary-material"}).

Selection Criteria {#s2a}
------------------

All randomised and quasi-randomised studies that compared two or more methods of recruiting study participants to a real phase III RCT or mock RCT (where no actual trial occurred) were included. Studies that assessed recruitment to observational studies, questionnaires, health promotional activities, and other health care interventions and nonrandomised studies of recruitment strategies were excluded. Where more than one publication of the same study existed, the publication with the most complete data was included.

Literature Search {#s2b}
-----------------

Studies were identified from MEDLINE (1950 to April, week 4, 2009), Embase (1980 to week 17, 2009), and The Cochrane Library (Cochrane Library, issue 3, 2009) ([Figure 1](#pmed-1000368-g001){ref-type="fig"}). The MEDLINE and Embase databases were searched using text words and subject headings (with unlimited truncations) for "recruitment," "enrolment," and "accrual" combined with "random" and "trials" and "participate" or "consent" or "recruit" with unlimited truncations. The Cochrane Library was searched using "recruitment" combined with "random and trial," and "consent or accrual." The search strategy changed slightly with time as a result of changes in MEDLINE Mesh heading definitions. Reference lists of relevant studies were also searched and non-English language papers were translated. Two of three reviewers (PHYC, AT, or SH) independently screened each study title and abstract for eligibility, retrieved full text articles of all potentially relevant studies, and extracted data from the retrieved papers using a form that was designed by the authors. Disagreements were resolved by discussion with a third reviewer (JCC).

![Literature search.](pmed.1000368.g001){#pmed-1000368-g001}

Data Extraction {#s2c}
---------------

Data were extracted without blinding to authorship, on the recruitment methods evaluated, the population setting, and the trial design, as well as risk of bias items such as randomisation, allocation concealment, blinding of outcome assessors, loss to follow up, and intention-to-treat analysis. These elements were each assessed separately using the method developed by the Cochrane Collaboration [@pmed.1000368-Higgins1].

Outcomes Assessed {#s2d}
-----------------

The primary outcome of interest was consent rates for the different recruitment strategies. Because studies differed in definitions of consent rates, where possible we recalculated the consent rate of each recruitment method by dividing the number of participants exposed to the recruitment method who actually consented for clinical study participation by the total number of potential participants exposed to that method (see [Figure 2](#pmed-1000368-g002){ref-type="fig"}). For studies where information was insufficient to calculate consent rates, other measures of consent success described in the study were reported. For mock trials, willingness to consent to participate (i.e., potential participants acknowledging that they would be willing to participate in the trial or willingness to be contacted for participation in future trials) was the outcome measure. Consent rates and other outcome measures were compared using intention-to-treat analysis.

![Consent rate for RCTs.](pmed.1000368.g002){#pmed-1000368-g002}

Statistical Methods {#s2e}
-------------------

Where possible we used relative risk (RR) and their 95% confidence intervals (CIs) to describe the effects of different strategies in individual recruitment trials. Where more than two strategies were used in a single recruitment trial, the numerator and denominator from the standard (control) recruitment strategy was divided by the number of intervention strategies for each comparison so that the control numbers would not be overrepresented [@pmed.1000368-Higgins1].

Results {#s3}
=======

Literature Search {#s3a}
-----------------

From 16,703 unique titles and abstracts, 396 articles were retrieved and 37 eligible publications identified ([Figure 1](#pmed-1000368-g001){ref-type="fig"}). Collectively this total assessed recruitment outcomes in at least 59,354 people who were approached for clinical study participation, of whom 18,812 consented to participate ([Table 1](#pmed-1000368-t001){ref-type="table"}). (Not all studies identified the number of potential participants who were approached).

10.1371/journal.pmed.1000368.t001

###### Included studies.

![](pmed.1000368.t001){#pmed-1000368-t001-1}

  Trial Type                                      Author                                     Year of Publication   Country of Trial               Health Problem Studied                                                 Intervention Arms of RCT                                    Recruitment Strategy Studied   *n* Recruited for Trial   *n* Invited to Participate in Trial
  ------------ ---------------------------------------------------------------------------- --------------------- ------------------ ------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------ ------------------------- -------------------------------------
  Treatment                             Du [@pmed.1000368-Coyne1]                                   2008                 USA                            Lung cancer                                                 Mixed treatments (multiple trials)                                  Information provision                 26                              126
                                     Hutchison [@pmed.1000368-Leira1]                               2007                  UK                         Multiple cancers                                               Mixed treatments (multiple trials)                                  Information provision                 128                             173
                                    Monaghan [@pmed.1000368-Pighills1]                              2006            Multinational                 BP control in diabetics                                            Antihypertensive versus placebo                                    Recruiter differences                7,847                         167 sites
                  Litchfield [@pmed.1000368-Hutchison1] [a](#nt101){ref-type="table-fn"}            2005                  UK                             Diabetes                                                      Two insulin delivery systems                                     Recruiter differences                 73                              80
                                      Kimmick [@pmed.1000368-Ellis1]                                2005                 USA                         Multiple cancers                                               Mixed treatments (multiple trials)                                  Recruiter differences                1,097                          unknown
                                    Nystuen [@pmed.1000368-Martinson1]                              2004                Norway                      Absentee employees                                                Follow up versus standard care                                    Information provision                 97                              703
                                     Donovan [@pmed.1000368-Quinaux1]                               2003                  UK                          Prostate cancer                                         Surgery versus radiotherapy versus monitoring                             Recruiter differences                 103                             150
                                    Coyne [@pmed.1000368-Mandelblatt1]                              2003                 USA                         Multiple cancers                                                 Chemotherapy (multiple trials)                                    Information provision                 147                             226
                                       Quinaux [@pmed.1000368-Du1]                                  2003                France                         Breast cancer                                                          Chemotherapies                                            Recruiter differences                 362                           unknown
                                      Tworoger [@pmed.1000368-Ford1]                                2002                 USA                           Breast cancer                                               Aerobic exercises versus stretching                                  Information provision                 376                            4,999
                                     Fleissig [@pmed.1000368-Simes1]                                2001                  UK                         Multiple cancers                                               Mixed treatments (multiple trials)                                  Recruiter differences                 205                     265 (15 recruiters)
                                 Miller [@pmed.1000368-LlewellynThomas1]                            1999                 USA                            Depression                                           Psychotherapy versus antidepressants versus both                           Recruiter differences                 50                              347
                                      Cooper [@pmed.1000368-Simel1]                                 1997                  UK                            Menorrhagia                                                 Medical management versus surgery                                        Trial design                     187                             273
                                      Berner [@pmed.1000368-Berner1]                                1997                 USA                      Gynaecological cancers                                            Mixed treatments (multiple trials)                                  Information provision                  9                              120
                                     Aaronson [@pmed.1000368-Cooper1]                               1996           The Netherlands                   Multiple cancers                                                 Chemotherapy (multiple trials)                                    Information provision                 146                             346
                                     Wadland [@pmed.1000368-Valanis1]                               1990                 USA                              Smoking                                                   Nicotine gum versus standard care                                   Information provision                 52                              104
                                      Simes [@pmed.1000368-Kiernan1]                                1986              Australia                      Multiple cancers                                               Mixed treatments (multiple trials)                                  Information provision                 50                              57
  Prevention                          Leira [@pmed.1000368-Miller1]                                 2009                 USA                       Aspiration pneumonia                                                 Ranitidine versus placebo                                       Information provision                 52                              100
                   Mandelblatt [@pmed.1000368-Lovato1] [a](#nt101){ref-type="table-fn"}             2005                 USA                           Breast cancer                                                   Tamoxifen versus Raloxifene                                      Information provision                 325                             450
                     Avenell [@pmed.1000368-Rogers1] [a](#nt101){ref-type="table-fn"}               2004                  UK                             Fractures                                                 Vitamins versus placebo/no treatment                                      Trial design                     367                             538
                                      Ford [@pmed.1000368-Monaghan1]                                2004                 USA                         Multiple cancers                                              Screening tests versus standard care                                 Information provision                 376                           12,400
                   Hemminki [@pmed.1000368-Fleissig1] [a](#nt101){ref-type="table-fn"}              2004               Estonia                  Postmenopausal health risks                                  Hormone replacement versus placebo/ no treatment                                Trial design                    1,823                           4,295
                                      Larkey [@pmed.1000368-Wragg1]                                 2002                 USA          cardiovascular disease, cancer and osteoporosis   Hormone replacement therapy and dietary modification and calcium and vitamin D supplements      Recruiter differences                 13                              34+
                                    Kendrick [@pmed.1000368-Swanson1]                               2001                  UK                            Home safety                                                 Safety equipment versus usual care                                  Information provision                 374                            2,397
                                     Kiernan [@pmed.1000368-Donovan1]                               2000                 USA                           Healthy diet                                      Additional goal setting techniques versus standard care                        Information provision                  9                              561
                     Welton [@pmed.1000368-Wadland1] [a](#nt101){ref-type="table-fn"}               1999                  UK               menopausal symptoms and osteoporosis                                Hormone replacement therapies versus placebo                                  Trial design                     150                          492 (438)
                                     Rogers [@pmed.1000368-Kendrick1]                               1998                 USA                 Risk for life threatening illness                                        Follow up versus standard care                                         Trial design                     44                              57
                                    Valanis [@pmed.1000368-Tworoger1]                               1998                 USA                            Lung cancer                                                      Vitamins versus placebo                                        Information provision                 451                           22,546
  Mock trial                        Halpern [@pmed.1000368-Aaronson1]                               2004                 USA                           Hypertension                                                      Different hypertensives                                       Incentives+trial design              66--94                            142
                                      Ellis [@pmed.1000368-Kimmick1]                                2002              Australia                        Breast cancer                                                  Chemotherapy versus Tamoxifen                                     Information provision                 26                              180
                 Martinson [@pmed.1000368-Easterbrook1] [a](#nt101){ref-type="table-fn"}            2000                 USA                 Smoking cessation and prevention                              Peer, mail, and phone contacts versus standard care                                Incentives                     1,560                           4,046
                                      Wragg [@pmed.1000368-Weston1]                                 2000                  UK                    Postmenopausal health risks                                         Hormone replacement versus placebo                                  Information provision                 22                              50
                                    Myles [@pmed.1000368-Litchfield1]                               1999              Australia                   Anaesthesia for surgery                                         Experimental drug versus standard care                                     Trial design                     429                             770
                     Weston [@pmed.1000368-Walson1] [a](#nt101){ref-type="table-fn"}                1997                Canada                       Premature labour                                           Induced labour versus expectant management                              Information provision                 43                              90
                      Gallo [@pmed.1000368-Larkey1] [a](#nt101){ref-type="table-fn"}                1995                Italy                      Hypothetical disease                                           Experimental drug versus standard drug                                     Trial design                    1,620                           2,035
                Llewellyn-Thomas [@pmed.1000368-Sackett1] [a](#nt101){ref-type="table-fn"}          1995                Canada                         Bowel cancer                                                   Chemotherapy versus monitoring                                    Information provision                 52                              102
                     Simel [@pmed.1000368-Nystuen1] [a](#nt101){ref-type="table-fn"}                1991                 USA                Variable presenting health problems                                       Standard versus new medication                                         Trial design                     55                              100
  Total                                                                                                                                                                                                                                                                                                                     18,812                          59,354+

Studies showed a statistically significant difference in consent rates between recruitment strategies.

BP, blood pressure.

Quality of Included Studies {#s3b}
---------------------------

There were 23 parallel group RCTs, six quasi-RCTs (including one using paired data), and eight cluster RCTs. Of the 37 included recruitment trials, only 12 studies (32%) had clear allocation concealment, two (4%) specified blinding of outcome assessors (no study had blinding of participants as this would have been difficult to achieve), 15 (40%) recorded loss to follow-up information, and 14 (38%) used intention-to-treat analysis (see [Table 2](#pmed-1000368-t002){ref-type="table"}).

10.1371/journal.pmed.1000368.t002

###### Quality of included studies.

![](pmed.1000368.t002){#pmed-1000368-t002-2}

  Trial Type                     Author                     Type Of RCT   Allocation Concealment   Blinding of Outcome Assessors   Loss to Follow Up Mentioned   Intention-to-Treat Analysis   Quality Items
  ------------ ------------------------------------------- ------------- ------------------------ ------------------------------- ----------------------------- ----------------------------- ---------------
  Prevention         Avenell [@pmed.1000368-Rogers1]         Parallel              Yes                          No                             Yes                           Yes                     3
  Prevention        Rogers [@pmed.1000368-Kendrick1]         Parallel              Yes                          Yes                            No                            Yes                     3
  Treatment        Monaghan [@pmed.1000368-Pighills1]       Cluster RCT            Yes                        Unclear                        Unclear                         Yes                     2
  Treatment         Hutchison [@pmed.1000368-Leira1]         Parallel              Yes                        Unclear                        Unclear                         Yes                     2
  Treatment           Cooper [@pmed.1000368-Simel1]          Parallel              Yes                          No                             No                            Yes                     2
  Treatment          Tworoger [@pmed.1000368-Ford1]          Parallel            Unclear                      Unclear                          Yes                           Yes                     2
  Treatment        Coyne [@pmed.1000368-Mandelblatt1]       Cluster RCT          Unclear                        No                             Yes                           Yes                     2
  Treatment             Du [@pmed.1000368-Coyne1]            Parallel            Unclear                        Yes                            Yes                           No                      2
  Prevention        Kendrick [@pmed.1000368-Swanson1]        Parallel              Yes                          No                             Yes                         Unclear                   2
  Prevention       Hemminki [@pmed.1000368-Fleissig1]        Parallel              Yes                          No                           Unclear                         Yes                     2
  Prevention         Ford [@pmed.1000368-Monaghan1]          Parallel            Unclear                        No                             Yes                           Yes                     2
  Prevention          Leira [@pmed.1000368-Miller1]          Parallel               No                        Unclear                          Yes                           Yes                     2
  Mock trial         Weston [@pmed.1000368-Walson1]          Parallel              Yes                          No                             Yes                         Unclear                   2
  Mock trial         Ellis [@pmed.1000368-Kimmick1]          Parallel              Yes                          No                             Yes                         Unclear                   2
  Mock trial    Llewellyn-Thomas [@pmed.1000368-Sackett1]    Parallel              Yes                          No                             Yes                           No                      2
  Mock trial     Martinson [@pmed.1000368-Easterbrook1]     Cluster RCT            Yes                          No                           Unclear                         Yes                     2
  Treatment         Donovan [@pmed.1000368-Quinaux1]         Parallel              Yes                          No                             No                            No                      1
  Treatment         Wadland [@pmed.1000368-Valanis1]         Parallel            Unclear                        No                             Yes                         Unclear                   1
  Treatment         Aaronson [@pmed.1000368-Cooper1]         Parallel            Unclear                        No                             Yes                         Unclear                   1
  Treatment          Berner [@pmed.1000368-Berner1]          Quasi-RCT              No                        Unclear                          Yes                         Unclear                   1
  Treatment        Nystuen [@pmed.1000368-Martinson1]        Parallel               No                        Unclear                        Unclear                         Yes                     1
  Prevention          Larkey [@pmed.1000368-Wragg1]         Cluster RCT          Unclear                        No                             Yes                           No                      1
  Prevention        Valanis [@pmed.1000368-Tworoger1]        Parallel            Unclear                        No                             No                            Yes                     1
  Prevention         Welton [@pmed.1000368-Wadland1]         Quasi-RCT              No                          No                             Yes                         Unclear                   1
  Mock trial         Simel [@pmed.1000368-Nystuen1]          Parallel            Unclear                        No                             No                            Yes                     1
  Treatment            Quinaux [@pmed.1000368-Du1]          Cluster RCT          Unclear                      Unclear                        Unclear                       Unclear                   0
  Treatment          Kimmick [@pmed.1000368-Ellis1]         Cluster RCT          Unclear                      Unclear                        Unclear                       Unclear                   0
  Treatment       Litchfield [@pmed.1000368-Hutchison1]     Cluster RCT          Unclear                      Unclear                        Unclear                       Unclear                   0
  Treatment          Fleissig [@pmed.1000368-Simes1]        Cluster RCT          Unclear                        No                             No                          Unclear                   0
  Treatment          Simes [@pmed.1000368-Kiernan1]          Parallel               No                          No                             No                          Unclear                   0
  Treatment      Miller [@pmed.1000368-LlewellynThomas1]     Quasi-RCT              No                          No                             No                          Unclear                   0
  Prevention        Kiernan [@pmed.1000368-Donovan1]         Parallel            Unclear                        No                             No                          Unclear                   0
  Prevention       Mandelblatt [@pmed.1000368-Lovato1]       Quasi-RCT              No                          No                           Unclear                       Unclear                   0
  Mock trial          Gallo [@pmed.1000368-Larkey1]          Parallel            Unclear                        No                             No                          Unclear                   0
  Mock trial        Myles [@pmed.1000368-Litchfield1]        Parallel            Unclear                        No                             No                          Unclear                   0
  Mock trial          Wragg [@pmed.1000368-Weston1]          Quasi-RCT           Unclear                        No                             No                          Unclear                   0
  Mock trial        Halpern [@pmed.1000368-Aaronson1]       Paired data             No                          No                           Unclear                       Unclear                   0

Characteristics of Included Studies {#s3c}
-----------------------------------

Of the 37 included studies, 17 assessed treatment comparisons, 11 were prevention studies, and nine mock studies (where participants declared their willingness to participate in a trial but no actual trial occurred).

There were 66 different types of recruitment strategies that were broadly categorised into four groups: novel trial designs (nine studies), recruiter differences (eight studies), incentives (two studies), and provision of trial information (19 studies), with one study looking at both novel trial design and incentives [@pmed.1000368-Halpern1]. Standard recruitment is defined as when the investigator invites the potential participant to enrol in the study and treatment allocation is randomly assigned after consent has been given, with routine treatment being provided where consent is not given.

Types of Recruitment Strategies Studied {#s3d}
---------------------------------------

### Novel trial designs {#s3d1}

Avenell and Hemminki [@pmed.1000368-Avenell1],[@pmed.1000368-Hemminki1] compared a standard placebo-controlled design with a nonblinded trial design (both for prevention studies) (see [Figure 3](#pmed-1000368-g003){ref-type="fig"} and [Table 3](#pmed-1000368-t003){ref-type="table"}). In the nonblinded trial design arm, randomisation occurred before participants were approached, and participants were informed of the treatment they were randomised to receive prior to giving consent. Consent rates were higher for the nonblinded trial design compared with standard trial design where randomisation occurred after consent for trial participation (RR 1.14, 95% CI 1.02--1.28 and RR 1.28, 95% CI 1.19--1.37, respectively) [@pmed.1000368-Avenell1],[@pmed.1000368-Hemminki1]. Welton [@pmed.1000368-Welton1] compared a noninferiority clinical study (where both arms of the trial had an active treatment) with a placebo-controlled study of hormone replacement for postmenopausal women. Willingness to enrol in the clinical study appeared to be higher for the noninferiority study compared with the placebo-controlled study, although results were only just statistically significant (39% versus 30%, RR 1.31, 95% CI 1.01--1.70).

![Consent rates for novel trial designs.\
RR, intervention recruitment strategy/standard recruitment strategy. Used total number/number of intervention strategies to calculate RR, so that the number of patients on standard strategies were not overrepresented; S, random assignment for participants, standard care for nonparticipants; 2, patients are told physician believes the experimental drug may be superior. Increased chance of receiving the experimental drug after consenting; 3, patients are told that they are allowed to increase or decrease their chance of receiving the new experimental drug after consenting; 4, experimental drug for participants, standard care for nonparticipants; 5, standard drug for participants, experimental drug for nonparticipants; 6, random assignment for participants, choice of either treatments for nonparticipants.](pmed.1000368.g003){#pmed-1000368-g003}

10.1371/journal.pmed.1000368.t003

###### Studies of novel trial designs.

![](pmed.1000368.t003){#pmed-1000368-t003-3}

  Study                                                                                   Standard Recruitment Strategy                                 *n/N*     Consent Rate (95% CI)                           Experimental Recruitment Strategies                              *n/N*      Consent Rate (95% CI)                      RR (95% CI)
  ---------------------------------------------------------- --------------------------------------------------------------------------------------- ----------- ----------------------- -------------------------------------------------------------------------------------- ------------ ----------------------- ---------------------------------------------------
  Myles [@pmed.1000368-Litchfield1]                                        One-sided informed consent[a](#nt104){ref-type="table-fn"}                  84/151         56% (48--64)                    One-sided physician modified[b](#nt105){ref-type="table-fn"}                 91/150         61% (52--69)                        1.10 (0.80--1.50)
                                                                                                                                                                                                       One-sided patient modified[c](#nt106){ref-type="table-fn"}                  85/150         57% (48--65)                        1.03 (0.75--1.41)
                                                                                                                                                                                                   Prerandomised to experimental drug[d](#nt107){ref-type="table-fn"}              90/169         53% (45--61)                        0.96 (0.70--1.33)
                                                                                                                                                                                                     Prerandomised to standard drug[e](#nt108){ref-type="table-fn"}                79/149         53% (45--61)                        0.96 (0.69--1.33)
  Gallo [@pmed.1000368-Larkey1]                                            One-sided informed consent[a](#nt104){ref-type="table-fn"}                  521/622        84% (81--87)                 Prerandomised to experimental drug[d](#nt107){ref-type="table-fn"}             642/730         88% (86--90)                        1.05 (0.98--1.12)
                                                                                                                                                                                                     Prerandomised to standard drug[e](#nt108){ref-type="table-fn"}               156/307         51% (45--56)        0.60 (0.53--0.69)[f](#nt109){ref-type="table-fn"}
                                                                                                                                                                                                       Two-sided informed consent[g](#nt110){ref-type="table-fn"}                 301/376         80% (76--84)                        0.95 (0.88--1.03)
  Avenell [@pmed.1000368-Rogers1]                                                      Standard placebo-controlled design                              233/358        65% (60--70)                                      Nonblinded trial design                                   134/180         74% (67--81)        1.14 (1.02--1.28)[f](#nt109){ref-type="table-fn"}
  Hemminki [@pmed.1000368-Fleissig1]                                                   Standard placebo-controlled design                             796/2,136       37% (35--39)                                      Nonblinded trial design                                  1,027/2159       48% (46--50)        1.28 (1.19--1.37)[f](#nt109){ref-type="table-fn"}
  Rogers [@pmed.1000368-Kendrick1]                                                     Opting-in consent for participation                              24/32         75% (57--89)                              Opting-out consent for nonparticipation                            20/25          80% (59--93)                        1.07 (0.81--1.41)
  Cooper [@pmed.1000368-Simel1]                                                             Standard informed consent                                  97/138         70% (62--78)              Partially randomised patient preference[h](#nt111){ref-type="table-fn"}            90/135         67% (58--75)                        0.95 (0.81--1.11)
  Simel [@pmed.1000368-Nystuen1]                              Consent for trial of usual treatment versus new treatment that may work twice as fast     35/52         67% (53--80)        Consent for trial of usual treatment versus new treatment that may work half as fast     20/48          41% (28--57)        0.62 (0.42--0.91)[f](#nt109){ref-type="table-fn"}
  Halpern [@pmed.1000368-Aaronson1] A- US\$100 incentive                                   10% risk of adverse effects                                  26/64         41% (29--54)                                    20% risk of adverse effects                                  23/64          36% (24--49)                        1.08 (0.59--2.00)
                                                                                           10% risk of adverse effects                                  26/64         41% (29--54)                                    30% risk of adverse effects                                  18/64          28% (18--41)                        1.44 (0.72--2.89)
                                                                                           20% risk of adverse effects                                  23/64         36% (24--49)                                    30% risk of adverse effects                                  18/64          28% (18--41)                        1.33 (0.65--2.72)
  Halpern [@pmed.1000368-Aaronson1] A- US\$1,000 incentive                                 10% risk of adverse effects                                  33/64         52% (39--64)                                    20% risk of adverse effects                                  26/64          41% (29--54)                        1.31 (0.77--2.22)
                                                                                           10% risk of adverse effects                                  33/64         52% (39--64)                                    30% risk of adverse effects                                  23/64          36% (24--49)                        1.42 (0.81--2.46)
                                                                                           20% risk of adverse effects                                  26/64         41% (29--54)                                    30% risk of adverse effects                                  23/64          36% (24--49)                        1.08 (0.59--2.00)
  Halpern [@pmed.1000368-Aaronson1] A- US\$2,000 incentive                                 10% risk of adverse effects                                  35/64         55% (42--67)                                    20% risk of adverse effects                                  29/64          45% (33--58)                        1.20 (0.74--1.94)
                                                                                           10% risk of adverse effects                                  35/64         55% (42--67)                                    30% risk of adverse effects                                  25/64          39% (27--52)                        1.38 (0.82--2.33)
                                                                                           20% risk of adverse effects                                  29/64         45% (33--58)                                    30% risk of adverse effects                                  25/64          39% (27--52)                        1.15 (0.66--2.02)
  Halpern [@pmed.1000368-Aaronson1] B- US\$100 incentive                                     10% assigned to placebo                                    21/62         34% (22--47)                                      30% assigned to placebo                                    20/62          32% (21--45)                        1.10 (0.55--2.21)
                                                                                             10% assigned to placebo                                    21/62         34% (22--47)                                      50% assigned to placebo                                    19/62          31% (20--44)                        1.10 (0.55--2.21)
                                                                                             30% assigned to placebo                                    20/62         32% (21--45)                                      50% assigned to placebo                                    19/62          31% (20--44)                        1.00 (0.49--2.06)
  Halpern [@pmed.1000368-Aaronson1] B- US\$1,000 incentive                                   10% assigned to placebo                                    27/62         44% (31--57)                                      30% assigned to placebo                                    25/62          40% (28--54)                        1.08 (0.61--1.90)
                                                                                             10% assigned to placebo                                    27/62         44% (31--57)                                      50% assigned to placebo                                    23/62          37% (25--50)                        1.17 (0.65--2.10)
                                                                                             30% assigned to placebo                                    25/62         40% (28--54)                                      50% assigned to placebo                                    23/62          37% (25--50)                        1.08 (0.59--1.99)
  Halpern [@pmed.1000368-Aaronson1] B- US\$2,000 incentive                                   10% assigned to placebo                                    28/62         45% (33--58)                                      30% assigned to placebo                                    26/62          42% (30--55)                        1.08 (0.61--1.90)
                                                                                             10% assigned to placebo                                    28/62         45% (33--58)                                      50% assigned to placebo                                    27/62          44% (31--57)                        1.00 (0.58--1.73)
                                                                                             30% assigned to placebo                                    26/62         42% (30--55)                                      50% assigned to placebo                                    27/62          44% (31--57)                        0.93 (0.53--1.64)
  Welton [@pmed.1000368-Wadland1]                                                      Standard placebo-controlled design                              65/218         30% (24--36)                                    Noninferiority trial design                                  85/218         39% (33--46)        1.31 (1.01--1.70)[f](#nt109){ref-type="table-fn"}

RR, experimental recruitment strategy/standard recruitment strategy. Used total number/number of experimental strategies to calculate RR, so that standard was not overrepresented. Halpern\'s study used each participant more than once.

Random assignment for participants, standard care for nonparticipants.

Patients told physician believes the experimental drug may be superior. Increased chance of receiving the experimental drug after consenting.

Patients are told that they are allowed to increase or decrease their chance of receiving the new experimental drug after consenting.

Experimental drug for participants, standard care for nonparticipants.

Standard drug for participants, experimental drug for nonparticipants.

Studies showed a statistically significant difference in consent rates between recruitment strategies.

Random assignment for participants, choice of either treatments for nonparticipants.

Patients could choose to be randomised or choose their own treatment, but only those who chose to be randomised were compared with standard treatment.

Gallo and Myles (both for mock studies) compared standard randomisation (random assignment for all participants and standard care for nonparticipants) with different types of randomisation designs [@pmed.1000368-Gallo1],[@pmed.1000368-Myles1]. Strategies included increasing or decreasing the chance of receiving the experimental treatment; experimental treatment for all participants and standard treatment for nonparticipants (where potential participants are informed that they have been randomised to receive the experimental treatment, but if they do not consent, they would receive the standard treatment); standard care for all participants and experimental treatment for nonparticipants (where potential participants are informed that they have been randomised to receive the standard treatment, but if they do not consent, they would receive the experimental treatment); and random assignment of treatment for participants and choice of treatment for nonparticipants. The only randomisation strategy that influenced consent was the "prerandomisation to standard drug" (standard care for all participants and experimental treatment for nonparticipants) in Gallo\'s study [@pmed.1000368-Gallo1], which significantly reduced the consent rate compared with standard randomisation (RR 0.60, 95% CI 0.53--0.69) [@pmed.1000368-Gallo1]. However, this was not demonstrated in Myles\' study [@pmed.1000368-Myles1].

Cooper compared standard consent with partially randomised patient preference where patients could choose to be randomised or choose their own (medical or surgical) treatment [@pmed.1000368-Cooper1]. Patients who chose their own treatment were excluded in our analysis, as choice of treatment conflicts with the purposes of random allocation of treatment, and only patients who chose to be randomised were compared with those receiving standard RCT consent (where they were offered the opportunity to participate in a clinical study where treatment was randomly allocated for participants). This study tested whether allowing a patient choice of treatments increased consent for choosing to have their treatment randomised, compared with simply inviting them to participate in a clinical RCT (without mentioning choice of treatment). There was no difference in consent rates between the standard consent and choosing to be randomised (RR 0.95, 95% CI 0.81--1.11).

Rogers compared "opting in" with "opting out" [@pmed.1000368-Rogers1] where consent was sought for participation or for nonparticipation, respectively. In the "opting out" arm, consent rate for clinical study participation was calculated as the proportion who did not sign the consent form (for refusing participation). There was no difference in consent rates between the two groups (RR 1.07, 95% CI 0.81--1.41).

Simel compared consenting to a clinical study assessing standard medication versus a new medication that worked twice as fast with a clinical study comparing standard medication with a new medication that worked half as fast as the standard medication [@pmed.1000368-Simel1]. Participants were not informed that this was a mock trial. This study was designed to assess patients\' competence and judgement regarding clinical study participation. Not surprisingly, more patients consented to a clinical study comparing the faster new medication than to a clinical study comparing a slower new medication (67% versus 41%, RR 0.62, 95% CI 0.42--0.91), with a more marked difference among those who voluntarily mentioned the medication\'s speed of action as a factor in their decision regarding clinical study participation, which may reflect better understanding of the trial information.

Halpern [@pmed.1000368-Halpern1] used a factorial design to assess willingness to participate in a number of mock trials using paired data from the same individuals with variations in clinical study designs (as well as variation in monetary incentives, which will be discussed later under "incentives"). There were no differences in consent rates statistically.

### Recruiter differences {#s3d2}

Eight recruitment trials compared recruiter differences (see [Figure 4](#pmed-1000368-g004){ref-type="fig"} and [Table 4](#pmed-1000368-t004){ref-type="table"}). Three cluster RCTs compared different strategies for engaging recruiters (e.g., standard contact versus additional monitoring and contact with recruiters [@pmed.1000368-Quinaux1]--[@pmed.1000368-Monaghan1]). Outcome measures were different for each of the studies and therefore results could not be combined. In Quinaux\'s study, 186 patients from 34 control centres enrolled compared with 176 total patients from 34 monitored centres [@pmed.1000368-Quinaux1]. In Kimmick\'s study, 1,161 elderly patients (36% of total patients in first year and 31% in second year) from the control centres enrolled compared with 1,075 (32% in first year and 31% in second year) from the centres who received additional training and contact with investigators [@pmed.1000368-Kimmick1]. Monaghan\'s study assessed median number of patients recruited per site with 37.0 patients from the 82 control sites compared with 37.5 patients from the 85 sites with increased contacts with investigators [@pmed.1000368-Monaghan1]. In all three studies, increased contact with investigators did not statistically increase consent rates, and appeared to actually lower enrolment. One recruitment trial that compared untrained recruiters with training of recruiters [@pmed.1000368-Larkey1] found statistically more patients enrolled when the recruiter was trained (28 trained recruiters enrolled 13 patients versus 28 untrained recruiters who enrolled no patients). Fleissig compared standard recruitment with providing recruiters with information about patient preferences [@pmed.1000368-Fleissig1], with no differences in consent rates between the two methods (RR 1.09, 95% CI 0.96--1.25).

![Consent rates for recruiter differences.\
RR, intervention recruitment strategy/standard recruitment strategy.](pmed.1000368.g004){#pmed-1000368-g004}

10.1371/journal.pmed.1000368.t004

###### Studies of recruiter differences.

![](pmed.1000368.t004){#pmed-1000368-t004-4}

  Study                                                          Standard Recruitment Strategy                                      *n/N*                 Consent Rate (95% CI)                                                         Experimental Recruitment Strategies                                                                       *n/N*                  Consent Rate (95% CI)                      RR (95% CI)
  ----------------------------------------- ------------------------------------------------------------------------ ----------------------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ----------------------- ---------------------------------------------------
  Donovan [@pmed.1000368-Quinaux1]                                  Recruitment by urologist                                        53/75                     71% (59--81)                                                                     Recruitment by nurse                                                                               50/75                      67% (55--77)                        0.94 (0.76--1.17)
  Miller [@pmed.1000368-LlewellynThomas1]                      Recruitment by senior investigator                                  28/162                     17% (12--24)                                                               Recruitment by research assistant                                                                        22/185                      12% (8--17)                        0.69 (0.41--1.15)
  Fleissig [@pmed.1000368-Simes1]            Standard consent, doctors not aware of patients\' personal preferences                96/130                     74% (65--81)        Doctors shown patient\'s responses to questionnaire regarding personal preferences and trial participation before recruiting patients for trial                109/135                     81% (73--87)                        1.09 (0.96--1.25)
  Litchfield [@pmed.1000368-Hutchison1]                            Paper-based data recording                                  28/28 screened                100% (88--100)                                                                    Internet data capture                                                                          45/52 screened                 87% (74--94)        0.87 (0.78--0.96)[a](#nt113){ref-type="table-fn"}
  Quinaux [@pmed.1000368-Du1]                                        Centres not monitored                                     186/34 centres                                                                                                    Monitored centres                                                                            176/34 centres                                    
  Larkey [@pmed.1000368-Wragg1]                                      Recruiters not trained                                    0/28 recruiters                                                                                                  Recruiters trained                                                                           13/28 recruiters                                   
  Kimmick [@pmed.1000368-Ellis1]                 Standard recruitment, website access and periodic notification       777 (year 1)+384 (year 2) = 1,161                            Additional seminar, educational materials, list of available protocols, email and mail reminders, and case discussion seminars for recruiters     691 year 1)+384 (year 2) = 1,075                           
  Monaghan [@pmed.1000368-Pighills1]                                  Usual communication                             37 (median) per site at 82 sites                                                           Frequent email contact and individual feedback about recruitment to the recruiter                                  37.5 (median) per site at 85 sites                          

RR, experimental recruitment strategy/standard recruitment strategy.

Studies showed a statistically significant difference in consent rates between recruitment strategies.

Donovan and Miller compared recruiter roles (doctor versus nurse RR 0.94, 95% CI 0.76--1.17 [@pmed.1000368-Donovan1], and senior investigator versus research assistant RR 0.69, 95% CI 0.41--1.15 [@pmed.1000368-Miller1]). Although there was no difference in consent rates between the recruiters, costs were higher for the more senior person (mean cost of £43.29 versus £36.40 and US\$78.48 versus US\$50.28 per patient randomised, respectively).

Litchfield compared internet-derived database handling with paper-based database handling [@pmed.1000368-Litchfield1]. Although proportionately more patients enrolled with the paper-based database, the internet database was more efficient (with shorter time required for data collection and more patients being exposed to the trial). 100% of paper-based database versus 87% internet database groups enrolled (RR 0.87, 95% CI 0.78--0.96), with the internet database being preferable for recruiters.

### Incentives {#s3d3}

Martinson and Halpern assessed incentives for increasing recruitment (see [Figure 5](#pmed-1000368-g005){ref-type="fig"} and [Table 5](#pmed-1000368-t005){ref-type="table"}) [@pmed.1000368-Halpern1],[@pmed.1000368-Martinson1]. In the Martinson study, compared to no incentives, any monetary incentive increased survey response rates and willingness to be contacted regarding a smoking cessation trial. The study did not measure actual recruitment to the clinical study. Consent rate for no incentives was 29% compared with 41% for prepaid US\$2 cash incentive (RR 1.43, 95% CI 1.19--1.72); 44% for US\$15 cash incentive contingent on completion of survey (RR 1.53, 95% CI 1.28--1.84); and 39% for US\$200 prize draw (RR 1.36, 95% CI 1.13--1.64).

![Consent rates for incentives.\
RR, intervention recruitment strategy/standard recruitment strategy. Used total number/number of intervention strategies to calculate RR, so that the number of patients on standard strategies were not overrepresented; S, random assignment for participants, standard care for nonparticipants; 1, small incentives (US\$2 prepaid cash incentive); 2, larger incentive (US\$15) contingent on response; 3, US\$200 prize draw.](pmed.1000368.g005){#pmed-1000368-g005}

10.1371/journal.pmed.1000368.t005

###### Studies of incentives.

![](pmed.1000368.t005){#pmed-1000368-t005-5}

  Study                                                             Standard Recruitment Strategy    *n/N*    Consent Rate (95% CI)            Experimental Recruitment Strategies              *n/N*     Consent Rate (95% CI)                      RR (95% CI)
  ---------------------------------------------------------------- ------------------------------- --------- ----------------------- ------------------------------------------------------- ----------- ----------------------- ---------------------------------------------------
  Martinson [@pmed.1000368-Easterbrook1]                                    No incentives           288/996       29% (26--32)                      US\$2 small prepaid cash                  423/1,021       41% (38--45)        1.43 (1.19--1.72)[a](#nt115){ref-type="table-fn"}
                                                                                                                                      Large cash incentives contingent on response (US\$15)   452/1,021       44% (41--47)        1.53 (1.28--1.84)[a](#nt115){ref-type="table-fn"}
                                                                                                                                                       US\$200 prize draw                     397/1008        39% (36--42)        1.36 (1.13--1.64)[a](#nt115){ref-type="table-fn"}
  Halpern [@pmed.1000368-Aaronson1] A-10% risk of adverse effect               US\$100               26/64        41% (29--54)                              US\$1,000                           33/64         52% (39--64)                        0.76 (0.45--1.30)
                                                                               US\$100               26/64        41% (29--54)                              US\$2,000                           35/64         55% (42--67)                        0.72 (0.43--1.21)
                                                                              US\$1,000              33/64        52% (39--64)                              US\$2,000                           35/64         55% (42--67)                        0.94 (0.60--1.48)
  Halpern [@pmed.1000368-Aaronson1] A-20% risk of adverse effect               US\$100               23/64        36% (24--49)                              US\$1,000                           26/64         41% (29--54)                        0.92 (0.30--1.70)
                                                                               US\$100               23/64        36% (24--49)                              US\$2,000                           29/64         45% (33--58)                        0.80 (0.45--1.43)
                                                                              US\$1,000              26/64        41% (29--54)                              US\$2,000                           29/64         45% (33--58)                        0.87 (0.50--1.51)
  Halpern [@pmed.1000368-Aaronson1] A-30% risk of adverse effect               US\$100               18/64        28% (18--41)                              US\$1,000                           23/64         36% (24--49)                        0.75 (0.37--1.53)
                                                                               US\$100               18/64        28% (18--41)                              US\$2,000                           25/64         39% (27--52)                        0.69 (0.35--1.39)
                                                                              US\$1,000              23/64        36% (24--49)                              US\$2,000                           25/64         39% (27--52)                        0.92 (0.50--1.70)
  Halpern [@pmed.1000368-Aaronson1] B- 10% assigned to placebo                 US\$100               21/62        34% (22--47)                              US\$1,000                           27/62         44% (31--57)                        0.79 (0.43--1.45)
                                                                               US\$100               21/62        34% (22--47)                              US\$2,000                           28/62         45% (33--58)                        0.70 (0.43--1.45)
                                                                              US\$1,000              27/62        44% (31--57)                              US\$2,000                           28/62         45% (33--58)                        1.00 (0.58--1.73)
  Halpern [@pmed.1000368-Aaronson1] B- 30% assigned to placebo                 US\$100               20/62        32% (21--45)                              US\$1,000                           25/62         40% (28--54)                        0.77 (0.40--1.48)
                                                                               US\$100               20/62        32% (21--45)                              US\$2,000                           26/62         42% (30--55)                        0.77 (0.40--1.48)
                                                                              US\$1,000              25/62        40% (28--54)                              US\$2,000                           26/62         42% (30--55)                        1.00 (0.56--1.80)
  Halpern [@pmed.1000368-Aaronson1] B- 50% assigned to placebo                 US\$100               19/62        31% (20--44)                              US\$1,000                           23/62         37% (25--50)                        0.83 (0.42--1.64)
                                                                               US\$100               19/62        31% (20--44)                              US\$2,000                           27/62         44% (31--57)                        0.71 (0.38--1.36)
                                                                              US\$1,000              23/62        37% (25--50)                              US\$2,000                           27/62         44% (31--57)                        0.86 (0.48--1.54)

RR, experimental recruitment strategy/standard recruitment strategy. Used total number/number of experimental strategies to calculate RR, so that standard was not overrepresented. Halpern\'s study used each participant more than once.

Studies showed a statistically significant difference in consent rates between recruitment strategies.

The Halpern study assessed the effect of variations in monetary incentives on the willingness to participate in a number of mock clinical studies (of varying trial designs that was mentioned earlier). Patients\' willingness to participate increased as the payment level increased from US\$100 to US\$2,000 irrespective of the risk of adverse effect and risk of being assigned to placebo, although the difference was not statistically significant.

### Methods of providing information {#s3d4}

Nineteen recruitment trials compared different methods of providing information to participants, including how the information was presented and what information was provided (see [Figure 6](#pmed-1000368-g006){ref-type="fig"} and [Table 6](#pmed-1000368-t006){ref-type="table"}).

![Consent rates for methods of providing information.\
RR, intervention recruitment strategy/standard recruitment strategy. Used total number/number of intervention strategies to calculate RR, so that the number of patients on standard strategies were not overrepresented; S, standard informed consent; B, bulk mailing; 1, enhanced recruitment letter and screening by African American interviewer; 2, enhanced recruitment letter, screening by African American interviewer and baseline information collected via telephone interview; 3, enhanced recruitment letter, screening by African American interviewer and church-based project sessions; 4, bulk mailing with letter; 5, first-class mailing; 6, first-class mailing with letter.](pmed.1000368.g006){#pmed-1000368-g006}

10.1371/journal.pmed.1000368.t006

###### Studies of methods of providing information.

![](pmed.1000368.t006){#pmed-1000368-t006-6}

  Study                                                                Standard Recruitment Strategy                             *n/N*      Consent Rate (95% CI)                                               Experimental Recruitment Strategies                                                  *n/N*      Consent Rate (95% CI)                      RR (95% CI)
  ------------------------------------------- ------------------------------------------------------------------------------- ------------ ----------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------ ----------------------- ---------------------------------------------------
  Kendrick [@pmed.1000368-Swanson1]                                 Standard informed consent (mailing)                        157/1,194        13% (11--15)                                                    Additional home safety questionnaire                                               217/1,203        18% (16--20)        1.37 (1.14--1.66)[a](#nt117){ref-type="table-fn"}
  Kiernan [@pmed.1000368-Donovan1]                             Standard informed consent (mailing of flyer)                      0/191            0% (0--2)                             Additional personal letter (combination of general letter+Hispanic specific letter)                          9/370            2% (1--5)                        9.83 (0.58--168.04)
  Valanis [@pmed.1000368-Tworoger1]                                 Standard informed consent (mailing)                        225/11,273         2% (2--6)                                        Advanced postcard 1 wk prior to mailing of recruitment packet                                   226/11,273         2% (2--2)                         1.0 (0.84--1.21)
  Nystuen [@pmed.1000368-Martinson1]                                Standard informed consent (mailing)                          42/347          12% (9--16)                                              Additional reminder phone call for nonresponders                                           55/356         15% (12--19)                        1.28 (0.88--1.85)
  Ford [@pmed.1000368-Monaghan1]               Standard informed consent (mailing)+screening[b](#nt118){ref-type="table-fn"}    95/3,297          3% (2--4)                                    Enhanced recruitment letter+screening by African American interviewer                                78/3,079          3% (2--3)                         0.87 (0.58--1.31)
                                                                                                                                                                    Enhanced recruitment letter+screening by African American interviewer+baseline information collected via telephone interview    87/3,075          3% (2--3)                         0.97 (0.65--1.45)
                                                                                                                                                                                Enhanced recruitment letter+screening by African American interviewer+church-based project sessions                116/2,949          4% (3--5)                         1.35 (0.92--1.99)
  Tworoger [@pmed.1000368-Ford1]                                          Bulk mailing no letters                               86/1,250          7% (6--8)                                                           Bulk mailing with letter                                                      87/1,251          7% (6--9)                         1.00 (0.67--1.50)
                                                                                                                                                                                                                   First class mailing no letters                                                  102/1,249         8% (7--10)                         1.17 (0.79--1.75)
                                                                                                                                                                                                                  First class mailing with letters                                                 101/1,249         8% (7--10)                         1.16 (0.78--1.73)
  Leira [@pmed.1000368-Miller1]                                          Standard informed consent                               25/50          50% (36--65)                                                  Advanced notification with phone and fax                                               27/50          54% (39--68)                        1.08 (0.74--1.57)
  Llewellyn-Thomas [@pmed.1000368-Sackett1]                         Tape recording of trial information                          21/50          42% (28--57)                                               Interactive computer program for participants                                             31/50          62% (47--75)        1.48 (1.00--2.18)[a](#nt117){ref-type="table-fn"}
  Weston [@pmed.1000368-Walson1]                                         Standard informed consent                               17/48          35% (22--51)                                                Additional video about the health condition                                              26/42          62% (46--76)        1.75 (1.11--2.74)[a](#nt117){ref-type="table-fn"}
  Berner [@pmed.1000368-Berner1]                                    Standard informed consent (verbal)                            4/50           7% (2--19)                                                Additional written cancer-specific information                                             4/56           7% (2--17)                         0.89 (0.24--3.38)
  Ellis [@pmed.1000368-Kimmick1]                                         Standard informed consent                               14/42          33% (20--50)                                                   Additional education booklet on trials                                                12/41          29% (16--46)                        0.88 (0.46--1.66)
  Du [@pmed.1000368-Coyne1]                                              Standard informed consent                               10/63           16% (8--27)                                                   Additional video about clinical trials                                                16/63          25% (15--38)                        1.60 (0.79--3.25)
  Hutchison [@pmed.1000368-Leira1]                                       Standard informed consent                               66/87          76% (66--84)                                              AVPI tool to explain about trials, video+DVD/CD                                            62/86          72% (61--81)                        0.95 (0.80--1.13)
  Coyne [@pmed.1000368-Mandelblatt1]                                     Standard informed consent                               93/137         68% (59--76)                                                       Easy-to-read consent statement                                                    67/89          75% (65--84)                        1.11(0.94--1.31)
  Wadland [@pmed.1000368-Valanis1]                                  Patients reading trial information                           25/53          47% (33--61)                                       Study coordinator reading and explaining the study to patients                                    27/51          53% (39--67)                        1.12 (0.76--1.65)
  Aaronson [@pmed.1000368-Cooper1]                                       Standard informed consent                               78/90          87% (78--93)                                             Additional phone-based contact with oncology nurse                                          68/90          76% (65--84)                        0.87 (0.76--1.01)
  Mandelblatt [@pmed.1000368-Lovato1]                              Standard informed consent (brochure)                         147/218         67% (61--74)                                    Additional brief educational session and discussion about the trial                                 178/232         77% (71--82)        1.14 (1.01--1.28)[a](#nt117){ref-type="table-fn"}
  Simes [@pmed.1000368-Kiernan1]                                             Total disclosure                                    23/28          82% (63--94)                                                            Individual approach                                                          27/29          93% (77--99)                        1.13 (0.93--1.38)
  Wragg [@pmed.1000368-Weston1]                            Explicit information[c](#nt119){ref-type="table-fn"}                   8/26          31% (14--52)                                           Ambiguous information[d](#nt120){ref-type="table-fn"}                                         14/24          58% (37--78)                        1.90 (0.97--3.70)

RR, experimental recruitment strategy/standard recruitment strategy. Used total number/number of experimental strategies to calculate RR, so that standard was not overrepresented.

Studies showed a statistically significant difference in consent rates between recruitment strategies.

Standard informed consent and screening (used total number/number of experimental strategies to calculate RR, so that standard was not overrepresented).

Provides the current best estimates of effect of the experimental treatment.

Emphasises the current state of uncertainty.

There were six recruitment trials that related to mailing of recruitment material for the clinical study. The methods used to enhance recruitment were the addition of: a questionnaire that focused on the health problem studied (Kendrick [@pmed.1000368-Kendrick1]); a personal letter inviting participation (Kiernan and Tworoger [@pmed.1000368-Kiernan1],[@pmed.1000368-Tworoger1]); use of bulk mailing or first class stamps (Tworoger [@pmed.1000368-Tworoger1]); an advanced postcard alerting recipients to look for the recruitment packet (Valanis [@pmed.1000368-Valanis1]); a reminder phone call for nonresponders of mailed recruitment material (Nystuen [@pmed.1000368-Nystuen1]); and increasingly intensive interventions (for African Americans), which included a follow-up eligibility-screening phone call, an enhanced recruitment letter featuring a prominent African American man, recruitment by an African American member of the research team, and involvement of church-based project sessions (Ford [@pmed.1000368-Ford1]). Kendrick\'s addition of the questionnaire that focused on the health problem studied (RR 1.37, 95% CI 1.14--1.66) [@pmed.1000368-Kendrick1] was the only mailing strategy that increased the consent rate compared with standard mailing of recruitment material. The personal letter [@pmed.1000368-Kiernan1],[@pmed.1000368-Tworoger1] using bulk mail or first class mail [@pmed.1000368-Tworoger1], advanced postcard warning [@pmed.1000368-Valanis1], and reminder phone calls [@pmed.1000368-Nystuen1] did not significantly increase consent rates (see [Table 6](#pmed-1000368-t006){ref-type="table"}).

Leira compared standard consent (being invited to participate in the clinical study when the investigators met the patient during helicopter retrievals) with advanced notification of the clinical study with telephone and faxing of informed consent documents prior to arrival of investigators in the helicopter [@pmed.1000368-Leira1]. The intention-to-treat analysis showed no statistical difference between the two recruitment strategies (RR 1.08, 95% CI 0.74--1.57), although 42% of the intervention group did not actually receive the intervention (fax and telephone call) because of technical and logistic reasons. Coyne compared an easy-to-read consent statement with standard consent [@pmed.1000368-Coyne1] but showed no significant difference in consent rates (RR 1.11, 95% CI 0.94--1.31).

Three recruitment trials looked at increasing participants\' understanding of the clinical trial process, which did not appear to affect recruitment [@pmed.1000368-Ellis1]--[@pmed.1000368-Hutchison1]. Ellis compared standard informed consent with the addition of an educational booklet on clinical trials [@pmed.1000368-Ellis1]. There was no difference in consent rates (unadjusted) between the two groups (RR 0.88, 95% CI 0.46--1.66). However, after adjusting for potential confounders (demographic variables, disease variables, preference for involvement in clinical decision making, anxiety, depression, and attitudes to clinical trials), participants receiving the educational booklets were significantly less likely to consent to clinical study participation (OR 0.22, 95% CI 0.04--1.0). Du compared standard care with the addition of a brief video about cancer clinical studies among patients with lung cancer [@pmed.1000368-Du1]. Consent rates were not statistically different between the two groups. Hutchison compared standard care (where patients discuss clinical care and clinical study participation with the administration of a trial-specific information sheet and consent form) with the addition of an audiovisual patient information tool (with choice of video, CD-Rom, or DVD format), which addressed clinical trial information [@pmed.1000368-Hutchison1], with no difference in consent rates between the two groups (76% versus 72%, RR 0.95, 95% CI 0.80--1.13).

Three recruitment trials assessed strategies that aim to increase participants\' understanding of their underlying condition. Llewellyn-Thomas compared tape recorded reading of clinical study information with an interactive computer program where participants (who were oncology patients receiving radiation therapy) were actively involved in the information search process [@pmed.1000368-LlewellynThomas1]. The consent rate was higher for participants in the interactive group (RR 1.48, 95% CI 1.00--2.18). Weston compared standard informed consent with the addition of a video explaining trial information and the health problem studied [@pmed.1000368-Weston1]. The consent rate was higher in the video group when initially assessed (RR 1.75, 95% CI 1.11--2.74), but this did not reach statistical significance at 2 wk follow-up (not shown on [Table 6](#pmed-1000368-t006){ref-type="table"}). Berner\'s recruitment trial compared standard care (verbal communication) with the addition of patient information files containing clinical information on cancer specific to the patient [@pmed.1000368-Berner1]. There was no difference in the rate of recruitment to cancer trials in both groups (7% versus 7%, RR 0.89, 95% CI 0.24--3.38), although not all patients were eligible for clinical study enrolment.

Three recruitment trials compared standard consent with additional personal contact with research staff (a study coordinator reading and explaining the clinical study, Wadland [@pmed.1000368-Wadland1]; additional phone-based contact with an oncology nurse, Aaronson [@pmed.1000368-Aaronson1]; and an additional educational session about the disease and risks and benefits of clinical study participation for an oncology prevention study, Mandelblatt [@pmed.1000368-Mandelblatt1]). There was no difference in consent rates between standard consent and the study coordinator reading and explaining the clinical study (RR 1.12, 95% CI 0.76--1.65) [@pmed.1000368-Wadland1] or additional phone-based contact with the oncology nurse (RR 0.87, 95% CI 0.76--1.01) [@pmed.1000368-Aaronson1]. However there was higher consent for participants who attended the education session (RR 1.14, 95% CI 1.01--1.28) [@pmed.1000368-Mandelblatt1].

There were two recruitment trials assessing framing of recruitment information. In Simes\' 1986 trial of recruitment for a cancer treatment study [@pmed.1000368-Simes1], total disclosure of information about the clinical study was compared with an individual approach where doctors informed patients about the clinical study in a manner they thought best. This study assessed both willingness to enrol in the clinical study and actual study participation. There were no differences in actual consent rates between the total disclosure and individual approach groups (RR 1.13, 95% CI 0.93--1.38). However, actual consent rates were higher than the stated willingness to participate in the clinical study (actual consent rates were 82% and 93% in the total disclosure and individual approach groups, respectively, compared with rates of 65% and 88%, respectively, for willingness to participate in the clinical study). Wragg compared framing of recruitment information explicitly (to provide the best current estimates of effect for the experimental treatment) with framing information ambiguously (to emphasise the uncertainty and relative costs and benefits of the experimental treatment) [@pmed.1000368-Wragg1]. There was no difference in consent rates between the "ambiguously framed" group and the "explicitly framed" group (RR 1.90, 95% CI 0.97--3.70).

Discussion {#s4}
==========

Trials of recruitment strategies have evaluated all steps in the recruitment process, including different methods of trial design, randomisation, provision of information, and recruiter differences. In this systematic review, we found that strategies that increased potential participants\' awareness of the health problem being studied by engaging them in the learning process significantly increased consent rates (both for "real" and mock trials). These strategies included the addition of a questionnaire that focused on the health problem studied and additional educational sessions, videos, and interactive programs about the diseases studied [@pmed.1000368-Kendrick1],[@pmed.1000368-LlewellynThomas1],[@pmed.1000368-Weston1],[@pmed.1000368-Mandelblatt1]. Strategies that increased understanding of the clinical trial process (e.g., provision of an educational booklet [@pmed.1000368-Ellis1], video [@pmed.1000368-Du1], or audiovisual patient information tool [@pmed.1000368-Hutchison1] on clinical trials or provision of an easy-to-read consent statement [@pmed.1000368-Coyne1]) showed no evidence of improved recruitment. This finding suggests that it is increased education about the health problem being studied rather than education about the clinical trial process that increased trial participation. There were insufficient data to evaluate whether the effects of the different recruitment strategies were constant across all health conditions, but no there was no clear trend for these strategies to be context specific (see [Table 1](#pmed-1000368-t001){ref-type="table"}).

The recruitment trials on how recruitment information was provided (the technique of information presentation, how information was framed, who presented the information, and when the information was presented) did not show a difference between strategies, demonstrating that how or when the information was presented or who presented the information did not influence recruitment, but rather the information provided. A recent study (which was published after completion of our last search update) also showed that publicity about the trial did not increase recruitment [@pmed.1000368-Pighills1].

Although a previous observational study showed that framing of recruitment information to emphasise uncertainty enhanced recruitment [@pmed.1000368-Leader1], when this was tested by the rigor of RCT methodology [@pmed.1000368-Simes1],[@pmed.1000368-Wragg1], we found that framing did not appear to influence recruitment. Unexpectedly we found that the role of the recruiter also did not show evidence of influencing recruitment (although costs were higher for senior recruiters [@pmed.1000368-Donovan1],[@pmed.1000368-Miller1]).

In our review, one recruitment trial identified that a noninferiority clinical study (with active treatment arms) had higher consent rates compared with a placebo-controlled clinical study. This finding is consistent with previous findings that patients preferred "trials with all active arms to placebo-controlled trials" [@pmed.1000368-Caldwell3]. Also, recruitment trials that compared standard placebo-controlled design with a nonblinded trial design demonstrated that patients were more willing to participate in a clinical study if they knew which treatment they were receiving when consenting, even if the treatment was randomly predetermined. These studies illustrate people\'s anxieties regarding the unknowns of clinical trial participation. Despite the higher consent rates for the nonblinded trial design, the differential loss to follow up in the two treatments arms of the nonblinded trial is likely to jeopardise validity of the results, as comparison of outcomes between the two treatment groups would be subject to selection bias. For example, patients may be more likely to drop out if they were unhappy with the treatment they were assigned. In the two included studies of nonblinded trial designs, there were higher drop outs in the active treatment arms compared with the placebo arms.

The inclusion of recruitment trials of recruitment to mock clinical studies enabled assessment of recruitment strategies, which for equity reasons would be difficult to compare (such as different randomisation designs, different monetary incentives). Some strategies may be acceptable when used in isolation, but inappropriate when more than one are used within the same clinical study: for example mock trials that tested the hypothesis that potential participants are more willing to participate in a study if they had an increased chance of receiving the experimental treatment is a strategy that has been adopted by many vaccine and other clinical studies in the belief that potential participants are more likely to participate if they believed they had a higher chance of receiving the (desirable) experimental treatment. However, we found that increasing the likelihood of receiving the experimental treatment [@pmed.1000368-Myles1] (or reducing the risk of receiving placebo) [@pmed.1000368-Halpern1] did not appear to affect the consent rate, demonstrating that people\'s decisions for clinical study participation are not influenced by whether they are more or less likely to receive a particular treatment. Other strategies are more controversial: for example, the only consent strategy that appeared to affect the consent rate for a mock trial was "prerandomisation to standard drug" [@pmed.1000368-Gallo1], where participants were given the standard drug and nonparticipants were given the experimental drug. Fewer people were willing to consent to this type of clinical study than to a clinical study of standard randomisation for all participants. It is unlikely that such a method could ethically be employed in a real situation. Monetary incentives appeared to increase consent compared to no monetary incentives [@pmed.1000368-Martinson1], but the amount of money appeared to be less important [@pmed.1000368-Halpern1].

As results of mock clinical studies are based on whether participants are willing to enrol in a clinical study (rather than whether they actually consented), extrapolation to real clinical studies may not be realistic. Stated "willingness to participate" and actual participation may also differ. In the recruitment trial comparing standard consent to the addition of a video explaining clinical trial information and the health problem studied for a mock clinical study, although statistically more participants from the video group were willing to enrol in the clinical study, this number became not statistically significant 2 wk later [@pmed.1000368-Weston1]. Conversely, in Sime\'s 1986 study [@pmed.1000368-Simes1], more participants actually consented to clinical study participation than had indicated willingness to participate, perhaps reflecting patients\' deference to doctors\' advice in the 1980s (when there was less emphasis on patient autonomy compared with today). It also showed the influence of the doctor on patient behaviour [@pmed.1000368-Caldwell3].

Although there have been two previous systematic reviews on strategies to enhance recruitment to research [@pmed.1000368-Mapstone1],[@pmed.1000368-Watson1], our study is the latest and has a more targeted and rigorous search method. We conducted a more comprehensive search (with inclusion of more databases than Watson\'s study [@pmed.1000368-Watson1]) and included earlier as well as later studies, and also studies of recruitment for mock trials to test recruitment strategies that would otherwise be difficult to compare for equity reasons. Our methods were also more rigorous (with two reviewers examining all titles, abstracts, and relevant papers) with an inclusion criteria targeting recruitment of participants for RCTs only (excluding studies about recruitment to observational studies, questionnaires, health promotional activities. and other health care interventions). We targeted recruitment to RCTs in which recruitment is more difficult because potential participants must consent to participation in research in which their treatment is unknown. The Mapstone study conducted in 2002 and published in 2007 [@pmed.1000368-Mapstone1] included recruitment for any type of research studies, and the Watson study [@pmed.1000368-Watson1], although targeting recruitment strategies used for RCTs, searched only from 1996 to 2004 with a limited number of electronic databases (without hand searching), using only the keywords "recruitment strategy" or "recruitment strategies." Our study has identified more studies than the previous reviews (37 compared with 14 and 15 studies), and provides a better understanding of the factors that influence clinical RCT participation for potential participants. Although both previous studies highlighted effective and ineffective strategies, there was no attempt to examine the differences between successful and unsuccessful recruitment strategies.

Our findings are consistent with the health belief model that people are more likely to adopt a health behaviour (such as participation in a clinical study) if they perceive they are at risk of a significant health problem [@pmed.1000368-Becker1]. The importance of informing potential participants about the health problem being studied and engaging them in the learning process is not only educational and constructive, but is also likely to enhance clinical trial participation.

Limitations {#s4a}
-----------

Because of major differences in recruitment methods, populations, and types of clinical studies that were recruiting as well as outcomes measured, we did not combine the results statistically in a meta-analysis. In many of the smaller recruitment trials, the failure to find a significant difference in consent rates could be related to the sample size (type II error). There may also be publication bias. However, as more than 70% (27/37) of the included studies had a nonsignificant result, we are hopeful that publication bias may be minimal. Given that the interventions we are considering are of noncommercial value we would suggest that publication bias may be less likely than for other interventions.

The majority of the included trials were conducted in developed countries, with a substantial proportion in the US. We acknowledge that developed countries\' health systems may be very different from those of less-developed countries and hence the results of this systematic review may not be generalizable to other countries.

The main limitation of the study, due to the prolonged conduct of the study (from 2000 to 2009), was that the search strategy had to be modified with subsequent search updates owing to changes in MEDLINE Mesh heading definitions. Because of these changes (and the large number of titles and abstracts searched), the reason for exclusion of each study cannot be provided. The abstract of the first version of this systematic review (which included nonrandomised studies owing to the lack of randomised recruitment trials on the subject at the time) was published in conference proceedings in 2002 [@pmed.1000368-Caldwell1], and a later version that was limited to randomised studies was published in conference proceedings in 2007 [@pmed.1000368-Caldwell2].

Conclusion {#s4b}
----------

Our systematic review of recruitment strategies for enhancing participation in clinical RCTs has identified a number of effective and ineffective recruitment strategies. Grouped together, the statistically significant strategies either engaged participants in learning about the health problem being studied and its impact on their health or else informed participants of the treatment they have been randomised to receive (nonblinded trial design). However, as there was differential loss to follow up in the different treatment arms with nonblinded trial design, this trial design is likely to jeopardise the validity of the results. The use of monetary incentives may also increase recruitment, but as this was tested in a mock trial, and as another mock trial did not show any difference in consent rates between different amounts of monetary incentives, this finding needs to be interpreted with caution.

Future RCTs of recruitment strategies that engaged participants in the learning process using various methods of delivering the recruitment material compared with standard recruitment may confirm the effectiveness of this concept. This research may be particularly useful for testing strategies that expose large number of potential participants to recruitment information such as interactive internet strategies.
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